87 citations
,
September 2006 in “Clinical Cancer Research” Protein Kinase C shows promise for cancer treatment, but more research is needed to develop effective inhibitors.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
13 citations
,
November 2021 in “Frontiers in Molecular Biosciences” Reducing reactive oxygen species can help treat nerve damage from platinum cancer drugs.
9 citations
,
November 2023 in “Supportive Care in Cancer”
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
36 citations
,
January 2012 in “Dermatology” Stopping gefitinib improved scalp condition in a woman with lung cancer.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
January 2018 in “Journal of the advanced practitioner in oncology” Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.
March 2025 in “Molecular Neurobiology”
February 2026 in “Frontiers in Medicine” Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
28 citations
,
March 2017 in “Scientific Reports” Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Early advanced therapies are crucial for better survival in aggressive insulinoma cases.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.